Trials / Completed
CompletedNCT02584920
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 87 (actual)
- Sponsor
- Shanghai Henlius Biotech · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Randomised, double-blind, parallel group study to compare PK and PD profiles between HLX01 and rituximab (MabThera®) in patients with CD20+ B-cell Lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HLX01 | |
| DRUG | Rituximab |
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2015-10-23
- Last updated
- 2022-05-09
Source: ClinicalTrials.gov record NCT02584920. Inclusion in this directory is not an endorsement.